抗病毒治疗对巨细胞病毒阳性前葡萄膜炎的影响:复发风险与角膜内皮细胞保护
回顾性队列研究纳入136例巨细胞病毒前葡萄膜炎患者,比较口服伐更昔洛韦后0.15%更昔洛韦与持续2%更昔洛韦的疗效。抗病毒治疗后复发率从2.87人年降至1.16人年(降低59.6%,P<0.0001),2%组严重角膜内皮细胞丢失更常见(70.0% vs 34.4%,P=0.003)。
要点
- 抗病毒治疗使复发率从2.87人年降至1.16人年,降低59.6%(P<0.0001)。
- 口服伐更昔洛韦后0.15%更昔洛韦组复发率降低54.3%,2%更昔洛韦组降低78.8%。
- 2%更昔洛韦组严重角膜内皮细胞丢失发生率70.0%,高于口服后0.15%组的34.4%(P=0.003)。
核心结论
- 巨细胞病毒前葡萄膜炎复发率很高,抗病毒治疗可显著降低复发率。
- 口服伐更昔洛韦对角膜内皮细胞的保护优于2%更昔洛韦,但降阶梯至0.15%更昔洛韦后复发增加。
研究设计与样本
- 回顾性队列研究,来自一家三级眼科中心和一家葡萄膜炎专科私人诊所。
- 纳入2015年5月至2024年3月接受抗病毒治疗的巨细胞病毒前葡萄膜炎患者,共136例,中位随访27个月(346.8人年)。
主要发现
- 治疗前复发率为2.87人年,治疗后降至1.16人年(降低59.6%,P<0.0001)。
- 治疗后98例(72.0%)出现复发,中位无复发生存期为5.0个月(95%CI 3.4-6.6),1年无复发生存率为31.0%。
- 口服后0.15%组(n=113)复发率降低54.3%,2%局部组(n=23)降低78.8%。
- 初始6周口服伐更昔洛韦阶段无复发。
- 2%局部组严重角膜内皮细胞丢失发生率为70.0%,口服后0.15%组为34.4%(P=0.003)。
关键数值与推荐
- 严重角膜内皮细胞丢失定义为较基线每年丢失≥5%。
- 复发率以每人年(PYs)表示。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the risk of recurrence of anterior uveitis (AU) with positive polymerase chain reaction results for cytomegalovirus (CMV)-AU before and after initiation of antiviral therapy and compare the efficacy and safety of 2 treatment strategies: (1) initial oral valganciclovir followed by topical 0.15% ganciclovir and (2) continuous topical 2% ganciclovir. DESIGN: Retrospective cohort study from a tertiary ophthalmic center and a uveitis-specialized private clinic. PARTICIPANTS: Patients with CMV-AU who received antiviral therapy from May 2015 to March 2024. METHODS: Clinical records were analyzed retrospectively across the study period. Patients were treated with (1) a 6-week course of oral valganciclovir, followed by 0.15% ganciclovir ointment (oral to 0.15% group), or (2) continuous treatment with 2% topical ganciclovir (2% topical group). Recurrence rates were compared for the year before and after treatment initiation, expressed per person-years (PYs). Recurrence-free survival was analyzed using Kaplan-Meier analysis. A severe corneal endothelial cell (EC) loss was defined as ≥5% yearly loss from the baseline. MAIN OUTCOME MEASURES: Recurrence rate (PYs) and a severe EC loss. RESULTS: A total of 136 patients were included, with a median follow-up of 27 months (346.8 PYs). The recurrence rate significantly decreased from 2.87 PYs before treatment to 1.16 PYs after treatment (59.6% reduction; P < 0.0001). Post-treatment recurrence occurred in 98 patients (72.0%) after treatment. The median recurrence-free survival was 5.0 months (95% confidence interval [CI], 3.4-6.6), with a 1-year recurrence-free survival rate of 31.0%. Recurrence rates were reduced by 54.3% in the oral to 0.15% group (n = 113) and by 78.8% in the 2% topical group (n = 23). No recurrences occurred during the initial 6-week oral valganciclovir phase. Severe EC loss was more frequent in the 2% topical group (70.0%) compared with the oral to 0.15% group (34.4%; P = 0.003). Multivariate logistic regression identified that 2% topical treatment, compared with the oral to 0.15% regimen, was associated with severe EC loss (Exp (B) = 3.68; P = 0.032), after adjusting for age, sex, total follow-up period, and total recurrence number. CONCLUSIONS: Cytomegalovirus AU exhibited a very high recurrence rate, which was significantly reduced by antiviral therapy. Oral valganciclovir preserved corneal EC better than 2% ganciclovir but featured increased recurrence after step-down to the 0.15% ganciclovir. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Park MH, Lee JY, Jeon SJ, et al. Impact of Antiviral Therapy in Cytomegalovirus-Positive Anterior Uveitis: Recurrence Risk and Corneal Endothelial Cell Protection. Ophthalmology. 2025. PMID: 40744357. doi:10.1016/j.ophtha.2025.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。